NCT03759366View on ClinicalTrials.gov

A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 28, 2018

Primary Completion Date

January 6, 2022

Study Completion Date

November 6, 2023

Conditions
Myasthenia GravisMyasthenia Gravis, Juvenile FormMyasthenia Gravis, Generalized
Interventions
DRUG

Eculizumab

Eculizumab will be administered by IV infusion.

Trial Locations (11)

19104

Research Site, Philadelphia

27599

Research Site, Chapel Hill

29425

Research Site, Charleston

33612

Research Site, Tampa

44308

Research Site, Akron

60611

Research Site, Chicago

65201

Research Site, Columbia

90078

Research Site, Los Angeles

350-0495

Research Site, Iruma-Gun

173-0003

Research Site, Itabashi-ku

162-8666

Research Site, Shinjuku-ku

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY